MX2020010113A - Composicion farmaceutica que comprende brexpiprazol. - Google Patents

Composicion farmaceutica que comprende brexpiprazol.

Info

Publication number
MX2020010113A
MX2020010113A MX2020010113A MX2020010113A MX2020010113A MX 2020010113 A MX2020010113 A MX 2020010113A MX 2020010113 A MX2020010113 A MX 2020010113A MX 2020010113 A MX2020010113 A MX 2020010113A MX 2020010113 A MX2020010113 A MX 2020010113A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
brexpiprazole
granulate
relates
present
Prior art date
Application number
MX2020010113A
Other languages
English (en)
Inventor
Katarzyna Wos-Latosi
Kamil Garbera
Original Assignee
Adamed Pharma S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Pharma S A filed Critical Adamed Pharma S A
Publication of MX2020010113A publication Critical patent/MX2020010113A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con una composición farmacéutica que comprende un granulado que comprende brexpiprazol, en donde el granulado se obtiene mediante granulación húmeda de un vehículo usando un líquido de granulación que es una solución de brexpiprazol en un sistema disolvente; la presente invención se relaciona también con un granulado utilizado en la composición farmacéutica y con una forma de dosificación unitaria que comprende la composición farmacéutica y con el método para fabricar una composición farmacéutica que comprende brexpiprazol.
MX2020010113A 2018-03-26 2019-03-21 Composicion farmaceutica que comprende brexpiprazol. MX2020010113A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18461541.7A EP3545950A1 (en) 2018-03-26 2018-03-26 Pharmaceutical composition comprising brexpiprazole
PCT/EP2019/057016 WO2019185432A1 (en) 2018-03-26 2019-03-21 Pharmaceutical composition comprising brexpiprazole

Publications (1)

Publication Number Publication Date
MX2020010113A true MX2020010113A (es) 2020-11-06

Family

ID=61768247

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010113A MX2020010113A (es) 2018-03-26 2019-03-21 Composicion farmaceutica que comprende brexpiprazol.

Country Status (13)

Country Link
EP (2) EP3545950A1 (es)
KR (1) KR20200136399A (es)
AU (1) AU2019245827B2 (es)
BR (1) BR112020019410A2 (es)
CA (1) CA3092948A1 (es)
CO (1) CO2020012962A2 (es)
EA (1) EA202092062A1 (es)
MX (1) MX2020010113A (es)
PH (1) PH12020551434A1 (es)
SG (1) SG11202008768VA (es)
UA (1) UA126702C2 (es)
WO (1) WO2019185432A1 (es)
ZA (1) ZA202006541B (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
GB2505860B (en) * 2011-06-27 2018-10-31 Shanghai Zhongxi Pharmaceutical Corp Aripiprazole medicament formulation and preparation method therefor
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
TW201332572A (zh) 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β-環糊精之藥物製劑
CN105412036A (zh) * 2015-12-24 2016-03-23 北京康立生医药技术开发有限公司 依匹哌唑口腔崩解片

Also Published As

Publication number Publication date
ZA202006541B (en) 2021-09-29
EP3773508A1 (en) 2021-02-17
EP3545950A1 (en) 2019-10-02
UA126702C2 (uk) 2023-01-11
CA3092948A1 (en) 2019-10-03
AU2019245827B2 (en) 2024-05-02
BR112020019410A2 (pt) 2021-01-05
CO2020012962A2 (es) 2020-10-30
EA202092062A1 (ru) 2020-11-03
WO2019185432A1 (en) 2019-10-03
PH12020551434A1 (en) 2021-09-01
SG11202008768VA (en) 2020-10-29
AU2019245827A1 (en) 2020-09-24
KR20200136399A (ko) 2020-12-07

Similar Documents

Publication Publication Date Title
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
PH12017502315B1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
JO3675B1 (ar) مشتقات هيدروكسي إستر جديدة،عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
MX2017010858A (es) Composicion para el tratamiento de enfermedades relacionadas con la interleucina 6.
SA517390586B1 (ar) مشتقات حمض هيدروكسي جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
EA201892838A1 (ru) Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их
GEP201706686B (en) Novel pyrrole compounds, preparation method thereof, and pharmaceutical compositions containing them
GEP201706704B (en) New phosphate compounds, process for their preparation and pharmaceutical compositions containing them
MX2019015744A (es) Composiciones farmaceuticas.
EA201691322A1 (ru) Фармацевтическая композиция ингибитора dpp-iv в комбинации с метформином
MX2016000794A (es) Composiciones farmaceuticas de pancreatina de potencia alta.
EA201790949A1 (ru) Замещенные 2,4-диаминохинолины в качестве новых противораковых средств
MX2020013162A (es) Comprimidos de liberacion inmediata que contienen un farmaco y procesos para formar los comprimidos.
EA202090508A1 (ru) Изготовление фармацевтических составов
EA032927B1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
EA201890419A1 (ru) ОТСЕЛЕКТИРОВАННЫЙ АМИД γ-ГИДРОКСИМАСЛЯНОЙ КИСЛОТЫ И ЕГО ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ ЗЛОУПОТРЕБЛЕНИЯ АЛКОГОЛЕМ
EA201691741A1 (ru) Фармацевтическая композиция
EA202090913A1 (ru) Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон
PH12020551434A1 (en) Pharmaceutical composition comprising brexpiprazole
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
EA201600400A1 (ru) Противоопухолевая фармацевтическая композиция, содержащая темозоломид, и способ ее получения
MX2020011170A (es) Derivados de 1-imidazotiadiazol-2h-pirrol-5-ona.
PH12019500992A1 (en) Directly tablettable matrix for producing tablets with extended active substance delivery
MX2018002786A (es) Composicion farmaceutica de vinpocetina.
GR1008366B (el) Διεργασια παραγωγης ταχεως αποσαθρουμενων αναβραζοντων σφαιριδιων, κοκκιων ή/και μειγματων τους